作者
GR Oxnard, JC-H Yang, H Yu, S-W Kim, H Saka, L Horn, K Goto, Y Ohe, H Mann, KS Thress, MM Frigault, K Vishwanathan, D Ghiorghiu, SS Ramalingam, M-J Ahn
发表日期
2020/4/1
期刊
Annals of Oncology
卷号
31
期号
4
页码范围
507-516
出版商
Elsevier
简介
Background
Osimertinib is a potent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study (NCT02143466) was designed to assess the safety and tolerability of osimertinib in combination with other targeted therapies: selumetinib (MEK1/2 inhibitor), savolitinib (MET-TKI), or durvalumab [anti-programmed cell death ligand 1 (anti-PD-L1) monoclonal antibody].
Patients and methods
Patients with advanced EGFR-mutant non-small-cell lung cancer and disease progression on a prior EGFR-TKI were enrolled and allocated to dose-escalating cohorts combining osimertinib 80 mg orally (p.o.) once a day with selumetinib (25–75 mg p.o. twice a day; continuous or intermittent), savolitinib (600–800 mg p.o. once a day), or durvalumab (3–10 mg/kg intravenous every 2 weeks).
Results
At data cut-off (28 February 2018), 77 patients were enrolled and …
学术搜索中的文章
GR Oxnard, JCH Yang, H Yu, SW Kim, H Saka, L Horn… - Annals of Oncology, 2020